Bildkälla: Stockfoto

Sprint Bioscience Q1 2023: VADA deal needed - Redeye

Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.

Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.
Börsvärldens nyhetsbrev
ANNONSER